Last reviewed · How we verify
New England Retina Associates — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Topical Prednisolone Acetate 1% | Topical Prednisolone Acetate 1% | marketed | Topical corticosteroid | Glucocorticoid receptor | Ophthalmology | |
| Ranibizumab injection and TTT - ICG based | Ranibizumab injection and TTT - ICG based | phase 3 | VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance | VEGF-A | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Al-Azhar University · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- Apotex Inc. · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Astion Pharma A/S · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for New England Retina Associates:
- New England Retina Associates pipeline updates — RSS
- New England Retina Associates pipeline updates — Atom
- New England Retina Associates pipeline updates — JSON
Cite this brief
Drug Landscape (2026). New England Retina Associates — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/new-england-retina-associates. Accessed 2026-05-17.